Disclosures for "Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Adults With Lennox-Gastaut Syndrome: Post-Hoc Analysis of Dose Effects From a Phase 3 Trial Rationale")
-
Dr. Bishop has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for zogenix. Dr. Bishop has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Medtronic. Dr. Bishop has stock in zogenix.
-
Peter Isquith has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Global Pharma Consultancy, LLC. Peter Isquith has received publishing royalties from a publication relating to health care.
-
Dr. Knupp has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for zogenix. Dr. Knupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for encoded. Dr. Knupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for stoke. The institution of Dr. Knupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW pharmaceuticals. Dr. Knupp has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsy Research.
-
Joseph Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epygenix. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. The institution of Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encoded Therapetucis. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Invitate. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Longboard. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwigh Biosciences. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Knopp Biosciences. Joseph Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Asceneuron. Joseph Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various Law Firms. Joseph Sullivan has received stock or an ownership interest from Epygenix Therapeutics. The institution of Joseph Sullivan has received research support from Zogenix. The institution of Joseph Sullivan has received research support from Marinus Pharmaceuticals. The institution of Joseph Sullivan has received research support from Stoke Therapeutics. The institution of Joseph Sullivan has received research support from Encoded Therapeutics. The institution of Joseph Sullivan has received research support from BioPharm solutions.
-
Rima Nabbout has nothing to disclose.
-
Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $0-$499 for serving as a Consultant for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix . The institution of Dr. Gil-Nagel has received research support from Jazz Pharmaceuticals. The institution of Dr. Gil-Nagel has received research support from PTC Therapeutics. The institution of Dr. Gil-Nagel has received research support from Zogenix. The institution of Dr. Gil-Nagel has received research support from Agencia Estatal Innovacion.
-
Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xenon Pharmaceuticals. Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Zynerba Pharmaceuticals. Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Atheneum Partners. Dr. Scheffer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BioMarin. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from National Health and Medical Research Council, Australia. The institution of Dr. Scheffer has received research support from Medical Research Future Fund, Australia. The institution of Dr. Scheffer has received research support from Medical Research Future Fund, Australia. The institution of Dr. Scheffer has received research support from Shenzhen Sanming Development Grant . Dr. Scheffer has received intellectual property interests from a discovery or technology relating to health care. Dr. Scheffer has received intellectual property interests from a discovery or technology relating to health care. Dr. Scheffer has received intellectual property interests from a discovery or technology relating to health care. Dr. Scheffer has received personal compensation in the range of $500-$4,999 for serving as a Travel/Conference/Speaker honoraria with BioMarin. Dr. Scheffer has received personal compensation in the range of $500-$4,999 for serving as a Travel/Conference/Speaker honoraria with UCB. Dr. Scheffer has received personal compensation in the range of $500-$4,999 for serving as a Travel/Conference/Speaker honoraria with Eisai. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board, Trial Investigator with UCB that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Eisai that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board with Rogcon that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board, Trial investigator with Zynerba Pharmaceuticals that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board with Chiesi that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Scientific Advisory Board, Trial investigator with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Journal Editorial Board with Neurology that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Journal Editorial Board with Epilepsy Currents that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Journal Editorial Board with Epileptic Disorders that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Ovid Therapeutics that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Consultant with Atheneum Partners that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with GW Pharmaceuticals that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Marinus that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Zogenix that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Ultragenyx that is relevant to AAN interests or activities. Dr. Scheffer has a non-compensated relationship as a Trial investigator with Anavex Life Sciences that is relevant to AAN interests or activities.
-
Stéphane Auvin has nothing to disclose.
-
Dr. Cross has nothing to disclose.
-
Renzo Guerrini has nothing to disclose.
-
Robert Roth has received publishing royalties from a publication relating to health care.
-
Dr. Gioia has received personal compensation in the range of $0-$499 for serving as a Consultant for Global Pharma Consultancy. Dr. Gioia has received publishing royalties from a publication relating to health care.
-
Dr. Lothe has received personal compensation for serving as an employee of UCB. Dr. Lothe has received personal compensation for serving as an employee of Zogenix International Limited. Dr. Lothe has stock in Zogenix .
-
Shikha Polega has received personal compensation for serving as an employee of UCB. Shikha Polega has stock in UCB. Shikha Polega has stock in Zogenix.